The competitive landscape is intensifying as new entrants focus on performance differentiation (e.g., higher cycle lifetime, PCC compatibility) and as established players expand through pre-packed offerings and global distribution
Our healthcare providers will work with you to determine the best schedule for your unique situation, ensuring you get the maximum benefit from your treatments
Motta EVS, Arnott RLW, Moran NA (2023) Caffeine consumption helps honey bees fight a bacterial pathogen
Scott to discuss your goals, health history, and whether GLP-1 therapy is right for you
In summary, recent CV outcomes trials with GLP-1RAs have shown promising benefits in CV care of T2D patients, and GLP-1RAs have been accordingly listed as a second line therapy in T2D patients with established atherosclerotic CV disease, alongside SGLT2 inhibitors [5, 6]